MCID: HMS001
MIFTS: 50

Hemosiderosis

Categories: Rare diseases, Metabolic diseases

Aliases & Classifications for Hemosiderosis

MalaCards integrated aliases for Hemosiderosis:

Name: Hemosiderosis 12 72 49 51 41 14 69
Iron Overload 41 69
Haemosiderosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12119
NCIt 46 C82892
SNOMED-CT 64 190849009 39011001

Summaries for Hemosiderosis

Disease Ontology : 12 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary : Hemosiderosis, also known as iron overload, is related to iron overload in africa and aceruloplasminemia. An important gene associated with Hemosiderosis is TF (Transferrin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Insulin receptor recycling. The drugs Deferiprone and Deferoxamine have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and heart, and related phenotypes are hematopoietic system and liver/biliary system

Wikipedia : 72 Hemosiderosis (AmE) or haemosiderosis (BrE) is a form of iron overload disorder resulting in the... more...

Related Diseases for Hemosiderosis

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 iron overload in africa 34.5 HFE TF
2 aceruloplasminemia 31.4 CP FTL TF
3 atransferrinemia 30.0 CP HAMP HFE SLC11A2 SLC40A1 TF
4 thalassemia 29.5 EPO HFE TF TFRC
5 hemoglobin h disease 29.5 EPO TF TFRC
6 liver cirrhosis 29.3 GPT HFE TF
7 microcytic anemia 28.8 EPO SLC11A2 TF TFRC
8 siderosis 28.8 HFE SLC40A1 TF TFRC
9 porphyria cutanea tarda 28.7 HAMP HFE TF TFRC
10 beta-thalassemia 28.5 EPO HAMP HFE TF TFRC
11 iron metabolism disease 28.1 CP EPO HFE SLC11A2 SLC40A1 TF
12 iron deficiency anemia 27.8 EPO HAMP HFE SLC11A2 SLC40A1 TF
13 hemochromatosis, type 1 26.6 CP FTL HAMP HFE SLC11A2 SLC40A1
14 deficiency anemia 26.6 CP EPO FTL HAMP HFE SLC11A2
15 hypochromic microcytic anemia with iron overload 12.6
16 anemia, hypochromic microcytic, with iron overload 1 12.5
17 pulmonary hemosiderosis 12.5
18 anemia, hypochromic microcytic, with iron overload 2 12.5
19 hemochromatosis, type 5 12.2
20 secondary pulmonary hemosiderosis 12.0
21 hemosiderosis, pulmonary, with deficiency of gamma-a globulin 11.9
22 superficial siderosis 11.6
23 gracile syndrome 11.1
24 fascioliasis 10.3 CP GPT
25 ancylostomiasis 10.3 CP TF
26 hfe-associated hereditary hemochromatosis 10.3 HFE SLC11A2
27 swayback 10.3 CP HFE
28 kwashiorkor 10.3 GPT TF
29 eales disease 10.2 CP TF
30 hepatitis 10.2
31 epileptic encephalopathy, early infantile, 36 10.2 CP TF
32 nonalcoholic steatohepatitis 10.2 GPT HFE
33 pure red-cell aplasia 10.1 EPO TF
34 celiac disease 1 10.1
35 hypochromic microcytic anemia 10.1 CP SLC11A2 TF
36 protein-energy malnutrition 10.1 CP GPT TF
37 angiomatous meningioma 10.1 TF TFRC
38 hemorrhagic fever 10.1 GPT TFRC
39 fetal erythroblastosis 10.1 EPO TFRC
40 analbuminemia 10.0 EPO GPT TF
41 vitamin b12 deficiency 10.0 EPO GPT TF
42 fibrosis of extraocular muscles, congenital, 1 10.0
43 glomerulonephritis 10.0
44 cerebritis 10.0
45 anemia of prematurity 9.9 EPO HAMP
46 heart disease 9.9
47 rhizomelic chondrodysplasia punctata, type 2 9.9 HAMP HFE
48 inherited metabolic disorder 9.9 HAMP HFE TF
49 folic acid deficiency anemia 9.9 EPO TF TFRC
50 restless legs syndrome 9.9 EPO SLC11A2 TFRC

Graphical network of the top 20 diseases related to Hemosiderosis:



Diseases related to Hemosiderosis

Symptoms & Phenotypes for Hemosiderosis

MGI Mouse Phenotypes related to Hemosiderosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 TFRC CP EPO HFE SLC11A2 SLC40A1
2 liver/biliary system MP:0005370 9.1 CP EPO HFE SLC11A2 SLC40A1 TFRC

Drugs & Therapeutics for Hemosiderosis

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 30652-11-0 2972
2
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70-51-9 2973
3
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 201530-41-8 5493381
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Metformin Approved Phase 4 657-24-9 4091 14219
8
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
9 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Iron Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antacids Phase 4,Not Applicable
12 Anti-Ulcer Agents Phase 4,Not Applicable
13 Gastrointestinal Agents Phase 4,Not Applicable
14 Proton pump inhibitors Phase 4,Not Applicable
15 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Liver Extracts Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
18 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
19 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Antifungal Agents Phase 4
22 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
23 Antirheumatic Agents Phase 4,Phase 2,Not Applicable
24 Calcineurin Inhibitors Phase 4
25 Cyclosporins Phase 4
26 Dermatologic Agents Phase 4
27 Immunosuppressive Agents Phase 4,Phase 2,Not Applicable
28 Hypoglycemic Agents Phase 4,Not Applicable
29 Trichostatin A Phase 4
30 Vitamins Phase 4,Phase 2,Not Applicable
31 Antilymphocyte Serum Phase 4
32 Iron Supplement Nutraceutical Phase 4,Phase 3,Not Applicable
33
Zinc Approved, Investigational Phase 3,Phase 1,Not Applicable 7440-66-6 32051 23994
34
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
35
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
36
Amlodipine Approved Phase 3,Phase 2,Not Applicable 88150-42-9 2162
37
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
38
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
39 Orange Approved, Nutraceutical Phase 3,Phase 2
40 tannic acid Approved, Nutraceutical Phase 3
41 Adjuvants, Immunologic Phase 2, Phase 3,Not Applicable
42 Epoetin alfa Phase 2, Phase 3,Phase 3,Not Applicable 113427-24-0
43 Hematinics Phase 2, Phase 3,Phase 3,Not Applicable
44 Antihypertensive Agents Phase 3,Phase 2,Not Applicable
45 calcium channel blockers Phase 3,Phase 2,Phase 1,Not Applicable
46 Calcium, Dietary Phase 3,Phase 2,Phase 1,Not Applicable
47 Vasodilator Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Ferric Compounds Phase 2, Phase 3
49 Ferric oxide, saccharated Phase 2, Phase 3
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 251)

# Name Status NCT ID Phase Drugs
1 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4 deferiprone
2 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
3 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4 Deferasirox
4 Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4 deferasirox:
5 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
6 ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox Completed NCT00466063 Phase 4 Deferasirox
7 Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
8 Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload Completed NCT00654589 Phase 4 Deferasirox
9 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
10 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
11 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
12 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
13 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4 Exjade
14 Combo Chelation Trial Completed NCT00901199 Phase 4 Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
15 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
16 Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Completed NCT01818726 Phase 4 ICL670A and standard immunosupressive therapy (Cyclosporine A);Immunosupressive therapy (Cyclosporine A)
17 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4 ICL670
18 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4 deferasirox
19 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
20 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
21 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
22 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
23 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
24 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia Active, not recruiting NCT01709838 Phase 4 ICL670 deferasirox
25 Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
26 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Not yet recruiting NCT03372083 Phase 4 Deferasirox
27 Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients Not yet recruiting NCT02225886 Phase 4 Ascorbic Acid
28 Eltrombopag in Children With Idiopathic Aplastic Anemia Not yet recruiting NCT03243656 Phase 4 Eltrombopag
29 Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Terminated NCT01326845 Phase 4 Deferasirox
30 An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old Withdrawn NCT01724138 Phase 4 Deferasirox
31 Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia Withdrawn NCT02069886 Phase 4 deferasirox
32 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
33 Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis Unknown status NCT01045525 Phase 3
34 Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Unknown status NCT00980421 Phase 3
35 Therapeutic Effects of Silymarin in Patients With B-thalassemia Major Unknown status NCT00999349 Phase 2, Phase 3 Silymarin (LEGALON);Placebo
36 Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients Unknown status NCT01398644 Phase 3
37 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
38 Safety, Tolerability, and Efficacy of Deferasirox in MDS Completed NCT00469560 Phase 3 Deferasirox
39 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3 deferasirox
40 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions Completed NCT00061750 Phase 3 ICL670;deferoxamine
41 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study Completed NCT01033747 Phase 2, Phase 3 Deferasirox;Deferasirox
42 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01395199 Phase 3 Amlodipine
43 A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload Completed NCT00171821 Phase 3 Deferasirox
44 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3 Deferasirox
45 Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients Completed NCT00529152 Phase 3 Deferiprone
46 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3 Amlodipine
47 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3 Deferasirox
48 Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3 deferiprone;placebo
49 Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Completed NCT01825512 Phase 3 Deferiprone;Deferasirox
50 Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy Completed NCT00202436 Phase 3

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: hemosiderosis

Genetic Tests for Hemosiderosis

Anatomical Context for Hemosiderosis

MalaCards organs/tissues related to Hemosiderosis:

38
Liver, Lung, Heart, Bone, Bone Marrow, Kidney, Brain

Publications for Hemosiderosis

Articles related to Hemosiderosis:

(show top 50) (show all 1090)
# Title Authors Year
1
The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature. ( 29332607 )
2018
2
A composite mouse model of aplastic anemia complicated with iron overload. ( 29434729 )
2018
3
Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. ( 29371322 )
2018
4
Hereditary hypochromic microcytic anemia associated with loss-of-function DMT1 gene mutations and absence of liver iron overload. ( 29178181 )
2018
5
Correlation of Pancreatic Iron Overload Measured by T2*-Weighted Magnetic Resonance Imaging in Diabetic Patients with I^-Thalassemia Major. ( 28762844 )
2017
6
SERUM FERRITIN CONCENTRATION IS NOT A RELIABLE BIOMARKER OF IRON OVERLOAD DISORDER PROGRESSION OR HEMOCHROMATOSIS IN THE SUMATRAN RHINOCEROS (DICERORHINUS SUMATRENSIS). ( 28920821 )
2017
7
Methylprednisolone pulse therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis. ( 28784257 )
2017
8
Screening for hemosiderosis in patients receiving multiple red blood cell transfusions. ( 28129458 )
2017
9
Idiopathic pulmonary hemosiderosis: Hemorrhagic flare after 6 years of remission. ( 28844597 )
2017
10
Welder's pulmonary hemosiderosis associated with systemic iron overload following exacerbation of acute adult T-cell leukemia/lymphoma. ( 28883221 )
2017
11
Auricular Hemosiderosis in a Diabetic Patient. ( 28859747 )
2017
12
Epilepsy caused by superficial hemosiderosis of the central nervous system. ( 29105005 )
2017
13
Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. ( 28460338 )
2017
14
Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. ( 28456904 )
2017
15
Identification of new BMP6 pro-peptide mutations in patients with iron overload. ( 28335084 )
2017
16
Idiopathic Pulmonary Hemosiderosis Mimicking Iron Deficiency Anemia: A Delayed Diagnosis? ( 28670434 )
2017
17
Corticosteroid in combination with leflunomide and mesenchymal stem cells for treatment of pediatric idiopathic pulmonary hemosiderosis. ( 28158572 )
2017
18
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. ( 28642302 )
2017
19
Hemochromatosis Protein (HFE) Knockout Mice As a Novel Model of Hemochromatosis: Implications for Study and Management of Iron-Overload Cardiomyopathy. ( 28558947 )
2017
20
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis. ( 28067690 )
2017
21
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. ( 28482720 )
2017
22
A Case of Idiopathic Pulmonary Hemosiderosis Presenting With Signs and Symptoms Mimicking Hemolytic Anemia. ( 27918350 )
2017
23
Renal Hemosiderosis among Iranian Transfusion Dependent I^-Thalassemia Major Patients. ( 28875008 )
2017
24
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). ( 28296163 )
2017
25
Idiopathic Pulmonary Hemosiderosis in a Child with Recurrent Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis. ( 28251009 )
2017
26
Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia. ( 28707012 )
2017
27
Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. ( 28866669 )
2017
28
Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis. ( 28720890 )
2017
29
Clinical and Laboratory Associations with Persistent Hyperferritinemia in 373 Black Hemochromatosis and Iron Overload Screening Study Participants. ( 28809726 )
2017
30
HFE gene mutation and iron overload in Egyptian pediatric acute lymphoblastic leukemia survivors: a single-center study. ( 28211293 )
2017
31
Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. ( 28815805 )
2017
32
The hepatocyte-specific HNF4I+/miR-122 pathway contributes to iron overload-mediated hepatic inflammation. ( 28655781 )
2017
33
Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. ( 26908385 )
2016
34
Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major. ( 27548334 )
2016
35
Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A. ( 27383256 )
2016
36
Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis. ( 27013087 )
2016
37
Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran. ( 26838079 )
2016
38
Iron Overload Leading to Torsades de Pointes in I^-Thalassemia and Long QT Syndrome. ( 26920202 )
2016
39
Frequency of Hereditary Hemochromatosis (HFE) Gene Mutations in Egyptian Beta Thalassemia Patients and its Relation to Iron Overload. ( 27335591 )
2016
40
Hereditary hemochromatosis: Dealing with iron overload. ( 27032055 )
2016
41
Effect of the Hemochromatosis Mutations on Iron Overload among the Indian I^ Thalassemia Carriers. ( 27561698 )
2016
42
Proteomic Profiling of Iron Overload-Induced Human Hepatic Cells Reveals Activation of TLR2-Mediated Inflammatory Response. ( 26999096 )
2016
43
Glutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major. ( 26288192 )
2016
44
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. ( 27106071 )
2016
45
Comparison of Tissue Elastography With Magnetic Resonance Imaging T2star and Serum Ferritin Quantification in Detecting Liver Iron Overload in Patients With in Thalassemia Major. ( 27650324 )
2016
46
Helicobacter pylori Associated With Pulmonary Hemosiderosis. ( 26741588 )
2016
47
Unusual presentation: Concurrent IgA deficiency and idiopathic pulmonary hemosiderosis. ( 27120139 )
2016
48
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone. ( 27789107 )
2016
49
Effect of Hereditary Hemochromatosis Gene (HFE) H63D and C282Y Mutations on Iron Overload in Sickle Cell Disease Patients. ( 27095682 )
2016
50
Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. ( 26405152 )
2016

Variations for Hemosiderosis

Expression for Hemosiderosis

Search GEO for disease gene expression data for Hemosiderosis.

Pathways for Hemosiderosis

Pathways related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 CP FTL SLC11A2 SLC40A1 TF TFRC
2
Show member pathways
12.08 CP FTL SLC11A2 SLC40A1 TF TFRC
3 11.63 EPO TF TFRC
4
Show member pathways
11.59 CP SLC11A2 SLC40A1
5 11.44 CP EPO TF TFRC
6 11.27 FTL SLC11A2 SLC40A1 TF
7 11.18 EPO TF
8 11.01 EPO SLC11A2
9 10.7 CP FTL SLC11A2 SLC40A1 TF TFRC
10 10.43 HAMP SLC11A2 SLC40A1 TF TFRC
11 10.21 HAMP HFE

GO Terms for Hemosiderosis

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CP EPO FTL HAMP TF TFRC
2 extracellular space GO:0005615 9.8 CP EPO GPT HAMP HFE TF
3 cytoplasmic vesicle GO:0031410 9.78 HFE SLC11A2 TF TFRC
4 perinuclear region of cytoplasm GO:0048471 9.76 HFE SLC11A2 TF TFRC
5 cell surface GO:0009986 9.71 EPO SLC11A2 TF TFRC
6 early endosome GO:0005769 9.62 HFE SLC11A2 TF TFRC
7 endosome membrane GO:0010008 9.61 SLC11A2 TF TFRC
8 clathrin-coated pit GO:0005905 9.54 TF TFRC
9 blood microparticle GO:0072562 9.54 CP TF TFRC
10 extracellular vesicle GO:1903561 9.52 SLC11A2 TFRC
11 clathrin-coated vesicle membrane GO:0030665 9.51 TF TFRC
12 recycling endosome GO:0055037 9.46 HFE SLC11A2 TF TFRC
13 basal part of cell GO:0045178 9.13 HFE SLC11A2 TF
14 HFE-transferrin receptor complex GO:1990712 8.8 HFE TF TFRC

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.89 CP HFE SLC11A2 SLC40A1 TF
2 acute-phase response GO:0006953 9.61 EPO HAMP HFE
3 transferrin transport GO:0033572 9.58 HFE TF TFRC
4 iron ion transport GO:0006826 9.56 FTL SLC11A2 SLC40A1 TF
5 liver regeneration GO:0097421 9.55 HAMP HFE
6 positive regulation of receptor-mediated endocytosis GO:0048260 9.54 HFE TF
7 response to vitamin A GO:0033189 9.52 EPO HAMP
8 copper ion transport GO:0006825 9.51 CP SLC11A2
9 response to iron ion GO:0010039 9.5 HAMP HFE SLC11A2
10 cellular response to iron ion GO:0071281 9.48 HFE TF
11 iron ion transmembrane transport GO:0034755 9.46 SLC11A2 SLC40A1
12 multicellular organismal iron ion homeostasis GO:0060586 9.46 HAMP HFE SLC11A2 SLC40A1
13 response to iron ion starvation GO:1990641 9.37 HAMP HFE
14 iron ion homeostasis GO:0055072 9.35 FTL HFE SLC11A2 SLC40A1 TF
15 cellular iron ion homeostasis GO:0006879 9.23 CP FTL HAMP HFE SLC11A2 SLC40A1

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ferric iron binding GO:0008199 9.26 FTL TF
2 transferrin receptor binding GO:1990459 9.16 HFE TF
3 iron ion transmembrane transporter activity GO:0005381 8.96 SLC11A2 SLC40A1
4 ferrous iron transmembrane transporter activity GO:0015093 8.62 SLC11A2 SLC40A1

Sources for Hemosiderosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....